{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:50:40Z","timestamp":1761897040266,"version":"3.44.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen Scientific Affairs, LLC."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.clinthera.2019.03.013","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T17:06:23Z","timestamp":1556211983000},"page":"866-881.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study"],"prefix":"10.1016","volume":"41","author":[{"given":"Robert","family":"Rifkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bismark","family":"Baidoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Maiese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2002","series-title":"Health Professional Version. PDQ Cancer Information Summaries","author":"Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ(R))","key":"10.1016\/j.clinthera.2019.03.013_bib1"},{"key":"10.1016\/j.clinthera.2019.03.013_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017. CA","volume":"67","author":"Siegel","year":"2017","journal-title":"A\u00a0Cancer J Clinicians"},{"key":"10.1016\/j.clinthera.2019.03.013_bib3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","article-title":"Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Kumar","year":"2017","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.clinthera.2019.03.013_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2017.02.007","article-title":"How have evolutions in strategies for the treatment of relapsed\/refractory multiple myeloma translated into improved outcomes for patients?","volume":"112","author":"Sonneveld","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2019.03.013_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-10-3366","article-title":"Oncogenomics to target myeloma in the bone marrow microenvironment","volume":"17","author":"Anderson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2019.03.013_bib6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fcgamma receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clinthera.2019.03.013_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.03.013_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2019.03.013_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.clinthera.2019.03.013_bib10","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clinthera.2019.03.013_bib11","unstructured":"DARZALEX\u00ae (Daratumumab) Prescribing Information 2\/2019. Accessed on February 27, 2019, http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf."},{"key":"10.1016\/j.clinthera.2019.03.013_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in\u00a0vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.03.013_bib13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.03.013_bib14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.03.013_bib15","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2019.03.013_bib16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.03.013_bib17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.03.013_bib18","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab Plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Analysis of CASTOR","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2019.03.013_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-018-0096-7","article-title":"Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma","volume":"7","author":"Usmani","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clinthera.2019.03.013_bib20","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Analysis of POLLUX.","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2019.03.013_bib21","series-title":"In Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone","article-title":"One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP)","author":"Dimopoulos","year":"2018"},{"year":"2018","series-title":"Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials","author":"Szabo","key":"10.1016\/j.clinthera.2019.03.013_bib22"},{"year":"2018","author":"Voorhees","key":"10.1016\/j.clinthera.2019.03.013_bib23"},{"year":"2018","author":"Avet-Loiseau","key":"10.1016\/j.clinthera.2019.03.013_bib24"},{"year":"2018","series-title":"Three-year follow up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (rd) alone in relapsed or refractory multiple myeloma (RRMM)","author":"Bahlis","key":"10.1016\/j.clinthera.2019.03.013_bib25"},{"year":"2018","series-title":"Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor","author":"Mateos","key":"10.1016\/j.clinthera.2019.03.013_bib26"},{"year":"2018","series-title":"Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed\/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies","author":"Usmani","key":"10.1016\/j.clinthera.2019.03.013_bib27"},{"key":"10.1016\/j.clinthera.2019.03.013_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA4","article-title":"Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study","volume":"34","author":"Palumbo","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"year":"2018","series-title":"The US Oncology Network","key":"10.1016\/j.clinthera.2019.03.013_bib29"},{"key":"10.1016\/j.clinthera.2019.03.013_bib30","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2019.03.013_bib31","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.2217\/fon-2018-0275","article-title":"Daratumumab and its use in the treatment of relapsed and\/or refractory multiple myeloma","volume":"14","author":"Chehab","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.clinthera.2019.03.013_bib32","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"year":"2017","series-title":"Split Dosing of Daratumumab (D) in a Phase 1b Study of D Plus Carfilzomib (K)-based Regimens in Patients (Pts) with Multiple Myeloma (MM)","author":"Usmani","key":"10.1016\/j.clinthera.2019.03.013_bib33"},{"key":"10.1016\/j.clinthera.2019.03.013_bib34","first-page":"1839","article-title":"Results of an interim safety analysis of a phase 2 study of daratumumab (dara) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in previously untreated and relapsed patients (pts) with multiple myeloma (MM)","volume":"130","author":"Yimer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.03.013_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clinthera.2019.03.013_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/2040620718816699","article-title":"A\u00a0real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting","volume":"10","author":"Rifkin","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clinthera.2019.03.013_bib37","first-page":"2833","article-title":"Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data","volume":"26","author":"Kim","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2019.03.013_bib38","first-page":"100215","article-title":"Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: observations from real-world data","volume":"14","author":"Kim","year":"2019","journal-title":"J\u00a0Bone Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:34Z","timestamp":1758963034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819301286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0149291819301286"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.03.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Janssen Scientific Affairs, LLC. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}